Aurobindo Pharma soars on planning to commence supplies to Europe from China facility from April
Aurobindo Pharma is currently trading at Rs 1167.50, up by 37.70 points or 3.34% from its previous closing of Rs 1129.80 on the BSE.
The scrip opened at Rs 1114.05 and has touched a high and low of Rs 1170.00 and Rs 1109.90 respectively. So far 5048 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1592.55 on 13-Sep-2024 and a 52-week low of Rs 985.00 on 13-Mar-2024.
Last one week high and low of the scrip stood at Rs 1207.70 and Rs 1109.90 respectively. The current market cap of the company is Rs 67808.59 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.49% and 6.69% respectively.
Aurobindo Pharma is all set to commence supplies to Europe from its China facility from April onwards. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up the production. The company has received European regulatory approvals and can initiate product supply to the market. The company expects good traction coming out of the China plant over the next 2-3 years.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
